Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Autor: Subbiah, V, Kreitman, RJ, Wainberg, ZA, Cho, JY, Schellens, JHM, Soria, JC, Wen, PY, Zielinski, CC, Cabanillas, ME, Boran, A, Ilankumaran, P, Burgess, P, Romero Salas, T, Keam, B

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, vol 33, iss 4

BackgroundCombined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0da9c95d7849b00189b84315608b4ae0
https://pubmed.ncbi.nlm.nih.gov/35026411

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

Autor: Remon, J, Caramella, C, Jovelet, C, Lacroix, L, Lawson, Andrew, Smalley, S, Howarth, K, Gale, Davina, Green, E, Plagnol, V, Rosenfeld, Nitzan, Planchard, D, Bluthgen, MV, Gazzah, A, Pannet, C, Nicotra, C, Auclin, E, Soria, JC, Besse, B

Background: Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::218c824277d1fafe61b827249ca91669

NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with cell-triggering receptors

Autor: Le Maux Chansac, B., Moretta, A., Vergnon, I., Opolon, P., Lecluse, Y., Grunenwald, D., Kubin, M., Soria, Jc, Chouaib, S., Mami-Chouaib, F.

Publikováno v: Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2005, 175(9), pp.5790-8

NK cells are able to discriminate between normal cells and cells that have lost MHC class I (MHC-I) molecule expression as a result of tumor transformation. This function is the outcome of the capacity of inhibitory NK receptors to block cytotoxicity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e71764def679ca3e1f5e6562ed41e4a1
https://hal.archives-ouvertes.fr/hal-00094543

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer.

Autor: Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB

Publikováno v: Clinical Lung Cancer; 2012 Sep, Vol. 13 Issue 5, p391-395, 5p

Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.

Autor: Abedallaa N, Tremblay L, Baey C, Fabre D, Planchard D, Pignon JP, Guigay J, Pechoux CL, Soria JC, de Montpreville VT, Besse B

Publikováno v: Journal of Thoracic Oncology; 2012 Jul, Vol. 7 Issue 7, p1179-1183, 5p